References

 
  1. 1
    Lublin F. History of modern multiple sclerosis therapy. J Neurol. 2005;252(S3):iii3-iii9. doi:10.1007/s00415-005-2010-6.
  2. 2
    Science Blog. FDA Licenses Interferon Beta-1B [news release]. US Food and Drug Administration; July 23, 1993.
  3. 3
    Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
    Neurology. 2006;67(7):1242-1249.
    doi:10.1212/01.wnl.0000237641.33768.
    8d.
  4. 4
    BETASERON [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; Rev. April 2016.
  5. 5
    The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655-655. doi:10.1212/wnl.43.4.655.
  6. 6
    Weller I, Saake A, Schreiner T, et al. Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b. Patient Preference and Adherence. 2015:9 951-959.
  7. 7
    Ziemssen T, Sylvester L, Rametta M, et al. Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™). Neurol Ther. 2015;4(2):125-136. doi:10.1007/s40120-015-0036-y.
  8. 8
    Bayer BETACONNECT. Red Dot 21. http://red-dot-21.com/design/bayer-betaconnect/. Accessed September 8, 2016.
  9. 9
    Piccio L, Cross AH. Immunology of multiple sclerosis. In: Geisser BS, ed. Primer on Multiple Sclerosis. New York, NY: Oxford University Press; 2011:47-59.
  10. 10
    Grazioli E, Mihai C, Weinstock-Guttman B. Temporal and clinical course of multiple sclerosis. In: Giesser BS, ed. Primer on Multiple Sclerosis. New York, NY: Oxford University Press; 2011:141-148.
  11. 11
    Lucchinetti CF. Taking a microscopic look at multiple sclerosis. In: Giesser BS, ed. Primer on Multiple Sclerosis. New York, NY: Oxford University Press; 2011:61-77.
  12. 12
    Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain. 2002;125(10):2202-2212. doi:10.1093/brain/awf235.
  13. 13
    Data on file. Bayer Healthcare Pharmaceuticals Inc. Whippany, NJ.
  14. 14
    BETACONNECT Instructions for Use. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.
  15. 15
    BETASERON [medication guide]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; Rev. September 2015.
back to top arrow
Back to
Top